• Corpus ID: 198111258

IL-17 A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure . A Single-center Experience

  title={IL-17 A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure . A Single-center Experience},
  author={Shany Sherman and Efrat Solomon-Cohen and Iris Amitay-Laish and Emmilia Hodak and Lev Pavlovsky}

Figures and Tables from this paper


Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience
Anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity in psoriatic patients with loss of efficacy in TNF-α and IL-12/23 inhibitors treatment.
Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study
Ixekizumab (anti‐IL17A) is effective as treatment for moderate‐to‐severe plaque psoriasis, but real‐life data on effectiveness and safety are currently very limited.
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice
Adalimumab profile was excellent in this 5-year retrospective observation, showing the clinical validity of interclass transitioning among anti-TNFα options.
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
Ixekizumab proved to be an effective and safe therapeutic option for patients with prior systemic therapies, including biological treatments with the same mechanism of action, and failure of secukinumab does not preclude future therapy success with a second IL-17A-directed therapy.
Comparative efficacy of biological treatments for moderate‐to‐severe psoriasis: a network meta‐analysis adjusting for cross‐trial differences in reference arm response
Multiple biological therapies are approved for the treatment of moderate‐to‐severe psoriasis and there are no new treatments on the market for this disease.
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
This data indicates that continuation of treatment with adalimumab in patients previously treated with etanercept is a viable option for the treatment of psoriasis with biologics.
Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis
Real‐life data on newer biological and biosimilar agents for moderate‐to‐severe psoriasis are lacking and need to be evaluated in order to provide real‐life information.